



Oncolife  
**Endometrial  
Carcinoma**

Mutation Analysis by NGS

A panel of genomic markers that helps in risk stratification and early detection of endometrial carcinoma in view of the rise in disease incidence and mortality

## Clinical Utility

- Diagnostic screening of 21 genes for prognosis, Risk & Clinical outcomes.
- Coverage of Genomic aberrations: Relevant **hotspots - Single-Nucleotide Variants (SNVs), Indels, Splice site mutations (DNA)**.
- Detection of particular gene variant in specific tumor type assist the clinicians to evaluate the prognostic and predictive role of somatic mutations in Endometrial carcinoma and its histological subtypes.
- Tertiary reporting platforms like GENEYX.

### AMC/ACMG/ASCO/CAP/NCCN/EMA/ESMO

Guidelines followed

ARID1I	BRCA1	BRCA2	BRAF	CHEK2	FGFR1	FGFR2
FGFR3	FGFR3	KRAS	MLH1	MSH2	MSH6	MUTYH
NTRK1	PMS2	POLD1	POLE	PTEN	RET	TP53

## Test Details

Test Code	Test Name	Components	Specimen Type	Methodology	TAT
ONCO0152	Pole single gene testing	Pole gene	Formalin fixed paraffin embedded block (FFPE)	NGS	15 days
ONCO0149	Oncolife Endometrial Basic panel	21 genes (hotspots - single-nucleotide variants (SNVs), indels, splice site mutations (DNA))		NGS	15 days
ONCO0150	Oncolife Endometrial comprehensive-1	21 genes + MSI (Fragment)		NGS, Sanger	15 days
ONCO0151	Oncolife Endometrial Comprehensive- 2	21 genes + MMR (IHC)		NGS, IHC	15days, 4 days